Global Contraceptive Devices Market

Contraceptive Devices Market Size, Share, Growth Analysis, By Product(Condoms, Subdermal Implants, Contraceptive Drugs, Vaginal Rings), By End user(Male and Female), By Region - Industry Forecast 2024-2031

Report ID: SQMIG35I2253 | Region: Global | Published Date: February, 2024
Pages: 157 | Tables: 63 | Figures: 75

Contraceptive Devices Market News

  • In April 2022, after receiving funding from the Bill and Melinda Gates Foundation, ProMed Pharma started the preclinical assessment of a brand-new, totally resorbable contraceptive implant.
  • In July 2021, after contacting a pharmacist, progestogen-only contraceptive pills will be sold over the counter at pharmacies without a prescription, according to the Medicines and Healthcare Products Regulatory Agency (MHRA).
  • In January 2021, Teva Pharmaceuticals has made the generic version of the vaginal ring NuvaRing (etonogestrel and ethinyl estradiol) available in the United States. These vaginal rings have been introduced, and it is anticipated that the market for vaginal rings as contraceptive methods will grow.
$5,300
BUY NOW GET FREE SAMPLE
Want to customize this report?

Our industry expert will work with you to provide you with customized data in a short amount of time.

REQUEST FREE CUSTOMIZATION

FAQs

Contraceptive Devices Market size was valued at USD 28.30 billion in 2022 and is poised to grow from USD 30.01 billion in 2023 to USD 48.06 billion by 2031, growing at a CAGR of 6.06% during the forecast period (2024-2031).

global contraceptive devices market features a highly competitive landscape with the presence of several key players. These companies focus on innovation, product development, strategic partnerships, and mergers and acquisitions to gain a competitive edge in the market. These key players, along with several other regional and local manufacturers, form a highly competitive landscape in the global market. Constant research and development, product diversification, and strategic partnerships remain crucial for companies to sustain growth and maintain a competitive advantage. 'Bayer AG (Germany)', 'Pfizer Inc. (US)', 'Janssen Global Services, LLC (US)', 'Teva Pharmaceutical Industries Ltd. (Jerusalem)', 'Merck Sharp & Dohme Corp. (US)', 'Mylan N.V. (US)', 'Reckitt Benckiser Group plc. (UK)', 'Veru Inc. (US)', 'Medisafe Distribution Inc. (Canada)', 'CooperSurgical, Inc. (US)', 'Devex (US)', 'Mayer Laboratories, Inc. (US)', 'Allergan plc (Ireland)', 'Agile Therapeutics (US)', 'HLL Lifecare (India)', 'ANSELL LTD (Australia)', 'Mankind Pharma (India)', 'TTK HealthCare (India)', 'Boehringer Ingelheim International GmbH. (Austria)', 'V-Care Pharma Pvt. Ltd. (India)'

One groundbreaking advancement in contraceptive technology is the development of a highly efficient, non-hormonal intrauterine device (IUD). This innovative device offers women a reliable and long-lasting method of birth control. By utilizing a unique design that promotes both safety and ease of use, this IUD provides a hassle-free contraceptive solution while minimizing potential side effects. It’s effectiveness and user-friendly nature make it a promising option for women seeking convenient and reliable contraception.

The market is being driven by a number of factors, such as rising unwanted pregnancy rates and increased understanding and use of family planning techniques. Additionally, the soaring prevalence of STIs and the increased government financing for family planning programmes are promoting market expansion. The availability of numerous contraceptive methods, such as condoms, intrauterine devices, oral contraceptives, and subdermal implants, as well as rising consumer spending power, are also contributing to the market's expansion. In addition, the rise of the e-commerce industry, the development of long-acting reversible contraceptives, and the escalating trend of product innovations are boosting the market. This is in accordance with the growing demand for non-hormonal and natural contraceptives and the rising popularity of female-controlled contraceptive techniques, both of which are fostering market expansion.

North America dominated the global Contraceptive Devices market. It holds a maximum revenue share of more than 32.90%. The region's high rates of abortion, growing population of women between the ages of 15 and 44, and high patient awareness levels during the predicted period. Teenagers' desire for contraceptives has increased because of the introduction of generic and inexpensive medications and technologies.

Request Free Customization

Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.

Click here right-arrow
logo-images

Related Reports

Contraceptives Market
Buy Now GET FREE SAMPLE
Contraceptive Drugs Market
Buy Now GET FREE SAMPLE
U.S. Contraceptive Market
Buy Now GET FREE SAMPLE
Hormonal Contraceptive Market
Buy Now GET FREE SAMPLE
Fertility Testing Devices Market
Buy Now GET FREE SAMPLE
Intrauterine Devices Market
Buy Now GET FREE SAMPLE
Women's Health Devices Market
Buy Now GET FREE SAMPLE
Non-Hormonal Contraception Market
Buy Now GET FREE SAMPLE

Feedback From Our Clients

Global Contraceptive Devices Market

Report ID: SQMIG35I2253

$5,300
BUY NOW GET FREE SAMPLE